Shares of Cerevel Therapeutics (CERE) dipped and are down about 2% in Wednesday morning trading. The weakness is being attributed to a report by CTFN, citing a source close to the matter, that a recommendation memo from the staff at the FTC to challenge the company’s planned merger with AbbVie (ABBV) is being considered, contacts tell The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERE: